Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?

Front Immunol

Laboratorio de Investigacao em Dermatologia e Imunodeficiencias, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Published: November 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Harnessing dendritic cells (DC) to treat HIV infection is considered a key strategy to improve anti-HIV treatment and promote the discovery of functional or sterilizing cures. Although this strategy represents a promising approach, the results of currently published trials suggest that opportunities to optimize its performance still exist. In addition to the genetic and clinical characteristics of patients, the efficacy of DC-based immunotherapy depends on the quality of the vaccine product, which is composed of precursor-derived DC and an antigen for pulsing. Here, we focus on some factors that can interfere with vaccine production and should thus be considered to improve DC-based immunotherapy for HIV infection.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305438PMC
http://dx.doi.org/10.3389/fimmu.2018.02993DOI Listing

Publication Analysis

Top Keywords

treat hiv
8
hiv infection
8
dc-based immunotherapy
8
dendritic cell-based
4
cell-based immunotherapy
4
immunotherapy treat
4
hiv strategy
4
strategy improved?
4
improved? harnessing
4
harnessing dendritic
4

Similar Publications

Background: With antiretroviral therapy, people with HIV can live a normal lifespan and not transmit HIV. The Ryan White HIV/AIDS Program provides care for over half of people with HIV in the United States.

Objective: To estimate how many HIV infections could result from cessation of Ryan White services or interruptions lasting 18 to 42 months.

View Article and Find Full Text PDF

Vδ1 γδ T cells are key players in innate and adaptive immunity, particularly at mucosal interfaces such as the gut. An increase in circulating Vδ1 cells has long been observed in people with HIV-1, but remains poorly understood. We performed a comprehensive characterization of Vδ1 T cells in blood and duodenal intra-epithelial lymphocytes, obtained from endoscopic mucosal biopsies of 15 people with HIV-1 on antiretroviral therapy and 15 HIV-seronegative controls, in a substudy of the ANRS EP61 GALT study (NCT02906137).

View Article and Find Full Text PDF

Despite the success of antiretroviral therapy in suppressing plasma viremia in people living with human immunodeficiency virus type-1 (HIV-1), persistent viral RNA expression in tissue reservoirs is observed and can contribute to HIV-1-induced immunopathology and comorbidities. Infection of long-lived innate immune cells, such as tissue-resident macrophages and microglia may contribute to persistent viral RNA production and chronic inflammation. We recently reported that de novo cytoplasmic expression of HIV-1 intron-containing RNA (icRNA) in macrophages and microglia leads to MDA5 and MAVS-dependent innate immune sensing and induction of type I IFN responses, demonstrating that HIV icRNA is a pathogen-associated molecular pattern (PAMP).

View Article and Find Full Text PDF

Background: Overweight and obesity are major concerns among people living with HIV (PLWH), particularly those on integrase inhibitors, as they elevate the risk of cardiovascular diseases. However, longitudinal data on the burden and risk factors for overweight/obesity in sub-Saharan Africa (SSA) remain limited. This study aimed to estimate the incidence and identify factors associated with overweight and obesity among PLWH who switched to a dolutegravir (DTG)-based ART regimen at Livingstone University Teaching Hospital.

View Article and Find Full Text PDF

Introduction: Despite increased national and international funding to combat the human immunodeficiency virus (HIV) pandemic, prison health services remain underfunded, resulting in poor HIV management among inmates. This study assessed viral suppression rates among HIV-positive inmates across four central prisons in Cameroon to evaluate the effectiveness of antiretroviral therapy (ART) in these settings.

Methodology: This cross-sectional study included four central prisons-prisons A, B, C, and D-each located in different regions of Cameroon.

View Article and Find Full Text PDF